NO20091598L - P-toluensulfonsyresalt av 5-amino-3-(2'-O-acetyl-3'-deoksy-beta-D-ribofuranosyl)-3H-tiazol(4,5-d)pyrimidin-2-on og fremgangsmater for fremstilling derav - Google Patents
P-toluensulfonsyresalt av 5-amino-3-(2'-O-acetyl-3'-deoksy-beta-D-ribofuranosyl)-3H-tiazol(4,5-d)pyrimidin-2-on og fremgangsmater for fremstilling deravInfo
- Publication number
- NO20091598L NO20091598L NO20091598A NO20091598A NO20091598L NO 20091598 L NO20091598 L NO 20091598L NO 20091598 A NO20091598 A NO 20091598A NO 20091598 A NO20091598 A NO 20091598A NO 20091598 L NO20091598 L NO 20091598L
- Authority
- NO
- Norway
- Prior art keywords
- ribofuranosyl
- deoxy
- acetyl
- amino
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Det beskrives p-toluensulfonsyresalt av 5-amino-3-(2'-O-acetyl-3'-deoksy-beta-D-ribofuranosyl)-3H-tiazolo[4,5-d]pyrimidin-2-on og dets anvendelse til behandling av slike tilstander som virusinfeksjoner, tumorer og cancer. Videre beskrives en fremgangsmåte for fremstilling av p-toluensulfonsyresalt av 5-amino-3-(2'-O-acetyl-3'-deoksy-?-D-ribofuranosyl)-3H-tiazolo[4,5-d]pyrimidin-2-on og fremgangsmåter for fremstilling av furanoseforbindelser som er anvendelige mellomprodukter ved fremstillingen av farmasøytiske forbindelser som p-toluensulfonsyresalt av 5-amino-3-(2'-O-acetyl-3'-deoksy-?-D-ribofuranosyl)-3H-tiazolo[4,5-d]pyrimidin-2-on og lignende.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85200206P | 2006-10-17 | 2006-10-17 | |
US89940507P | 2007-02-05 | 2007-02-05 | |
US95359707P | 2007-08-02 | 2007-08-02 | |
PCT/US2007/081526 WO2008140549A1 (en) | 2006-10-17 | 2007-10-16 | P-TOLUENE SULFONIC ACID SALT OF 5-AMINO-3-(2'-O-ACETYL-3'-DEOXY-β-D-RIBOFURANOSYL)-3H-THIAZOLE [4, 5-D] PYRIMIDINE-2-ONE AND METHODS FOR PREPARATION |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20091598L true NO20091598L (no) | 2009-07-10 |
Family
ID=39472747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20091598A NO20091598L (no) | 2006-10-17 | 2009-04-22 | P-toluensulfonsyresalt av 5-amino-3-(2'-O-acetyl-3'-deoksy-beta-D-ribofuranosyl)-3H-tiazol(4,5-d)pyrimidin-2-on og fremgangsmater for fremstilling derav |
Country Status (25)
Country | Link |
---|---|
US (2) | US7928085B2 (no) |
EP (1) | EP2076132B1 (no) |
JP (2) | JP5279715B2 (no) |
KR (2) | KR101486444B1 (no) |
AR (1) | AR063484A1 (no) |
AU (1) | AU2007353381B2 (no) |
BR (1) | BRPI0717741A2 (no) |
CA (2) | CA2898225A1 (no) |
CY (1) | CY1113368T1 (no) |
DK (1) | DK2076132T3 (no) |
DO (1) | DOP2007000131A (no) |
EA (1) | EA017005B1 (no) |
ES (1) | ES2390930T3 (no) |
HK (1) | HK1132429A1 (no) |
IL (2) | IL198180A (no) |
MX (1) | MX2009004028A (no) |
MY (1) | MY150408A (no) |
NO (1) | NO20091598L (no) |
NZ (1) | NZ576408A (no) |
PE (1) | PE20081105A1 (no) |
PL (1) | PL2076132T3 (no) |
PT (1) | PT2076132E (no) |
TW (1) | TWI415854B (no) |
UY (1) | UY30650A1 (no) |
WO (1) | WO2008140549A1 (no) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2655904C (en) | 2006-06-22 | 2014-11-18 | Anadys Pharmaceuticals, Inc. | Prodrugs of 5-amino-3-(3'-deoxy-.beta.-d-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione |
US20110166092A1 (en) * | 2007-08-20 | 2011-07-07 | Anadys Pharmaceuticals, Inc. | Dosing methods for treating disease |
RS61612B1 (sr) | 2014-12-08 | 2021-04-29 | Hoffmann La Roche | 3-supstituisana 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-dion jedinjenja za lečenje i profilaksu virusne infekcije |
US9676793B2 (en) | 2014-12-23 | 2017-06-13 | Hoffmann-Laroche Inc. | Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same |
KR20170113658A (ko) | 2015-03-16 | 2017-10-12 | 에프. 호프만-라 로슈 아게 | Tlr7 작용제 및 hbv 캡시드 조립 억제제를 사용하는 병용 치료 |
CN107743491B (zh) | 2015-05-08 | 2020-08-21 | 豪夫迈·罗氏有限公司 | 用于治疗和预防病毒感染的新的氧硫杂环戊烷甲酸及其衍生物 |
CN107592864B (zh) | 2015-05-12 | 2021-04-16 | 豪夫迈·罗氏有限公司 | 用于治疗和预防病毒感染的新的取代的氨基噻唑并嘧啶二酮 |
WO2017001307A1 (en) | 2015-06-30 | 2017-01-05 | F. Hoffmann-La Roche Ag | Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection |
BR112019013884A2 (pt) | 2017-01-06 | 2020-03-03 | F. Hoffmann-La Roche Ag | Processo para a preparação de compostos de 5 -amino -6h´ -tiazolo [4,5 -d] pirimidina -2,7 -diona 3 -substituídos |
CN110007010A (zh) * | 2018-01-05 | 2019-07-12 | 大鹏药品工业株式会社 | 源自曲氟尿苷的类似物质的检测方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07224081A (ja) * | 1994-02-10 | 1995-08-22 | Kobayashi Koryo Kk | デオキシリボフラノシルハライド誘導体の製造方法 |
US5532374A (en) * | 1995-06-06 | 1996-07-02 | Hitachi Chemical Company, Ltd. | Method of preparation of bis-quinolines |
JP4067226B2 (ja) * | 1999-04-01 | 2008-03-26 | 三井化学株式会社 | 1―ハロゲノ−2−デオキシリボフラノース誘導体の製造方法 |
JP2000327693A (ja) * | 1999-05-21 | 2000-11-28 | Mitsui Chemicals Inc | 2’−デオキシ−β−シチジン誘導体の製造方法 |
US6649761B2 (en) * | 2001-05-30 | 2003-11-18 | Merck & Co., Inc. | Process for preparing piperazinepentaneamide HIV protease inhibitors |
JP4493337B2 (ja) * | 2001-11-27 | 2010-06-30 | アナディス ファーマシューティカルズ インク | 3−β−D−リボフラノシルチアゾロ[4,5−d]ピリミジンヌクレオシド及びその使用 |
CA2548608A1 (en) * | 2002-12-09 | 2004-06-24 | Texcontor Etablissement | Anhydrous crystalline form of valacyclovir hydrochloride |
OA13310A (en) * | 2003-09-05 | 2007-04-13 | Anadys Pharmaceuticals Inc | TLR7 ligands for the treatment of hepatitis C. |
BRPI0418887A (pt) * | 2004-06-07 | 2007-10-30 | Anadys Pharmaceuticals Inc | nucleosìdeos de 3-beta-d-ribofuranossiltiazol[4,5-d] pirimidina e usos dos mesmos |
PT1824482E (pt) * | 2004-12-17 | 2014-05-13 | Anadys Pharmaceuticals Inc | Compostos 3h-oxazolo e 3h-tiazolo[4,5-d]pirimidin-2-ona 3,5- -di-substituídos e 3,5,7-tri-substituídos e seus pró- -fármacos |
US7501526B2 (en) * | 2005-01-20 | 2009-03-10 | Taigen Biotechnology | Synthesis of polyamine compounds |
CA2655904C (en) * | 2006-06-22 | 2014-11-18 | Anadys Pharmaceuticals, Inc. | Prodrugs of 5-amino-3-(3'-deoxy-.beta.-d-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione |
EP2105445A4 (en) * | 2006-12-08 | 2014-01-22 | Api Corp | PROCESS FOR THE PREPARATION OF A FURANOSEDERIVATE |
-
2007
- 2007-10-06 BR BRPI0717741-0A2A patent/BRPI0717741A2/pt not_active Application Discontinuation
- 2007-10-16 TW TW096138583A patent/TWI415854B/zh not_active IP Right Cessation
- 2007-10-16 JP JP2009533481A patent/JP5279715B2/ja not_active Expired - Fee Related
- 2007-10-16 MX MX2009004028A patent/MX2009004028A/es active IP Right Grant
- 2007-10-16 WO PCT/US2007/081526 patent/WO2008140549A1/en active Application Filing
- 2007-10-16 MY MYPI20091559 patent/MY150408A/en unknown
- 2007-10-16 CA CA2898225A patent/CA2898225A1/en not_active Abandoned
- 2007-10-16 CA CA2666537A patent/CA2666537C/en not_active Expired - Fee Related
- 2007-10-16 EP EP07873546A patent/EP2076132B1/en not_active Not-in-force
- 2007-10-16 PE PE2007001399A patent/PE20081105A1/es not_active Application Discontinuation
- 2007-10-16 PT PT07873546T patent/PT2076132E/pt unknown
- 2007-10-16 PL PL07873546T patent/PL2076132T3/pl unknown
- 2007-10-16 NZ NZ576408A patent/NZ576408A/en not_active IP Right Cessation
- 2007-10-16 DK DK07873546.1T patent/DK2076132T3/da active
- 2007-10-16 EA EA200970387A patent/EA017005B1/ru not_active IP Right Cessation
- 2007-10-16 ES ES07873546T patent/ES2390930T3/es active Active
- 2007-10-16 AU AU2007353381A patent/AU2007353381B2/en not_active Ceased
- 2007-10-16 KR KR1020097010038A patent/KR101486444B1/ko active IP Right Grant
- 2007-10-16 US US11/873,202 patent/US7928085B2/en not_active Expired - Fee Related
- 2007-10-16 KR KR1020147026217A patent/KR101515077B1/ko active IP Right Grant
- 2007-10-17 DO DO2007000131A patent/DOP2007000131A/es unknown
- 2007-10-17 AR ARP070104611A patent/AR063484A1/es unknown
- 2007-10-17 UY UY30650A patent/UY30650A1/es not_active Application Discontinuation
-
2009
- 2009-04-16 IL IL198180A patent/IL198180A/en active IP Right Grant
- 2009-04-22 NO NO20091598A patent/NO20091598L/no not_active Application Discontinuation
-
2010
- 2010-01-05 HK HK10100028.4A patent/HK1132429A1/xx not_active IP Right Cessation
-
2011
- 2011-03-23 US US13/069,426 patent/US8193342B2/en not_active Expired - Fee Related
-
2012
- 2012-09-28 CY CY20121100897T patent/CY1113368T1/el unknown
- 2012-11-19 IL IL223126A patent/IL223126A/en active IP Right Grant
-
2013
- 2013-05-21 JP JP2013107302A patent/JP5703334B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20091598L (no) | P-toluensulfonsyresalt av 5-amino-3-(2'-O-acetyl-3'-deoksy-beta-D-ribofuranosyl)-3H-tiazol(4,5-d)pyrimidin-2-on og fremgangsmater for fremstilling derav | |
NO20055496L (no) | Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer | |
BRPI0511078A (pt) | compostos de pirimidinona cìclicos, composição compreendendo os mesmos, método de inibição e uso | |
CL2007003635A1 (es) | Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer. | |
ATE553105T1 (de) | Azetidin-analoge ais nucleosidase- und phosphorylase-hemmer | |
WO2004041203A3 (en) | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | |
NZ543467A (en) | The severe acute respiratory syndrome coronavirus | |
BRPI0418351A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo | |
BR0310106A (pt) | Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica | |
BRPI0512974A (pt) | novos derivados de hidantoìna para o tratamento de doenças obstrutivas das vias aéreas | |
NO20082026L (no) | Deazapuriner som er nyttige som inhibitorer for Janus-kinaser | |
SG170828A1 (en) | Deazapurines useful as inhibitors of janus kinases | |
WO2007140191A3 (en) | Glucose transport inhibitors and methods of use | |
NO20072548L (no) | Xantinderivater med HM74A reseptoraktivitet | |
WO2005110994A8 (en) | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | |
CR7043A (es) | Derivados de eteres utiles como ganetes inhibidores de las isozimas pde4 | |
BRPI0607770A2 (pt) | compostos de nucleosideo tricìclico para tratamento de infecções virais | |
NO20070782L (no) | Tetrapeptidanaloger. | |
GEP20115283B (en) | Pyrrolopyrimidine compounds and their uses | |
BRPI0513278A (pt) | uso de um composto, composto, composição farmacêutica, processo para produzir um composto, e, método para causar a morte celular através de terapia de ativação por fóton | |
WO2003080582A3 (de) | Fredericamycin-derivate | |
WO2006133099A3 (en) | Sirna microbicides for preventing and treating viral diseases | |
NO20073367L (no) | Makrolider | |
WO2007076085A3 (en) | Fused pyrimidones and thiopyrimidones, and uses thereof | |
BRPI0513513A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito inibitório de eg5 e um efeito anticáncer em um animal de sangue quente, e para tratar carcinomas em um animal de sangue quente |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |